A trial looking at chemotherapy followed by chemotherapy and radiotherapy together for locally advanced cervical cancer (CXII)

Cancer type:

Cervical cancer

Status:

Results

Phase:

Phase 2

This trial tried to find out if chemotherapy followed by chemotherapy and radiotherapy together improved treatment for women with locally advanced cancer of the cervix (cervical cancer).

More about this trial

If it can’t be removed with surgery, doctors usually treat cervical cancer with chemotherapy and radiotherapy at the same time. This is called chemoradiation.

Early research had shown that giving chemotherapy on its own before chemoradiation may be helpful. But doctors weren’t sure how well this would work. All treatments have side effects and it is important that people don’t have extra treatments they don’t need.

In this trial, women with locally advanced cervical cancer had chemotherapy followed by chemoradiation. The aim of the trial was to find out if the extra chemotherapy was useful. And to find out more about the side effects of this new combination of treatment.

Summary of results

The trial team found that having chemotherapy before chemoradiation was possible and useful for women with locally advanced cervical cancer.

This was a phase 2 trial. It recruited 46 women with locally advanced cervical cancer. Everyone had paclitaxel and carboplatin chemotherapy before having cisplatin and radiotherapy (chemoradiation).

The trial team were able to look at how well cervical cancer responded to initial chemotherapy in 44 women. They found that

  • In 2 women there was no sign of cancer – complete response Open a glossary item
  • In 30 women the cancer had shrunk – partial response Open a glossary item
  • In 10 women the cancer had stayed the same size – stable disease Open a glossary item
  • In 2 women the cancer had got worse

3 months after completing all their treatment (chemotherapy and chemoradiation), the trial team were able to look at how well the cervical cancer had responded in 43 women. They found that

  • In 29 women there was no sign of cancer
  • In 10 women the cancer had shrunk
  • In 2 women their cancer had stayed the same
  • In 2 women the cancer had got worse

At 3 and 5 years after treatment, the trial team found that about 7 out of every 10 women (70%) were still alive and free of cancer.

Overall the worst side effect from treatment was a drop in blood cells causing an increased risk of infection, bruising and bleeding. Other side effects reported included feeling and being sick, diarrhoea and constipation.

The trial team concluded that treating cervical cancer with chemotherapy followed by chemoradiation was possible and useful. They have used the results of this trial to design a bigger, international phase 3 trial to find out how useful this combination of treatment is for cervical cancer.

We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) and published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Mary McCormack

Supported by

Bristol-Myers Squibb
Cancer Research UK & UCL Cancer Trials Centre
NIHR Clinical Research Network: Cancer
NIHR University College London Hospitals Biomedical Research Centre
University College London (UCL)

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

668

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Charlie took part in a trial to try new treatments

A picture of Charlie

“I think it’s really important that people keep signing up to these type of trials to push research forward.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think